A new research review shows no clear advantages for new long-acting insulin drugs compared with older insulin treatments for type 2 diabetes.
The reviewers included Karl Horvath, MD, of the internal medicine department at Austria's University of Graz.
They reviewed eight studies with a combined total of nearly 2,300 adults taking insulin therapy for type 2 diabetes.
The studies were published in medical journals between 2001 and 2006. They lasted for about six months to one year and took place in Europe, North America, South America, and Africa.
Each study was designed differently. Together, they compared an older insulin treatment called NPH to two newer, long-acting insulin treatments: Levemir (insulin detemir) and Lantus (insulin glargine).